Study Title: Randomized Phase 2 Trial of Sacituzumab Govitecan With or Without Pembrolizumab in First-line Metastatic PD-L1-negative TNBC
For more information about the trial above please contact the study team:Medical University of South CarolinaPrincipal Investigator, Sivapiragasam, Abirami, at sivapira@musc.edu.Study Coordinator, Gelardi, Theresa, at gelardi@musc.edu.Trial opened at the following institutions: Medical University of South Carolina